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The Federal Audit of
Implantable Cardioverter-Defibrillator Implants
Lessons Learned
Jonathan S. Steinberg, MD, Suneet Mittal, MD
New York, New York; and Ridgewood, New Jersey
The federal government has investigated a large number of institutions regarding concerns that implantable
cardioverter-defibrillator procedures were performed in violation of the criteria set forth in a National Coverage
Determination. We describe our experience and responses to such an audit, as well as the to complexities and
nuances of practicing evidence-based medicine in the setting of heavy regulatory oversight. (J Am Coll Cardiol
2012;59:1270–4) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.026Practice guidelines endorse the use of an implantable
cardioverter-defibrillator (ICD) in patients with chronic left
ventricular dysfunction (1). Although a significant number
of eligible patients are never referred for this life-saving
therapy, a recently published study has raised concern that
many patients undergoing ICD implantation do not meet
these practice guidelines (2).
Over the past year, the Department of Justice (DOJ) has
been conducting a civil investigation to determine whether
some institutions had submitted claims for payment for
implantation of ICDs that were not medically indicated or
violated the Centers for Medicare and Medicaid (CMS)
payment policy. The period covered by this investigation
dates back to 2003 when CMS expanded coverage for
primary prevention ICD indications (Table 1). A major
focus of this inquiry has been the exclusion of coverage
during the 40 days after acute myocardial infarction (MI) or
the 3 months after percutaneous coronary intervention
(PCI) or surgical revascularization. Although ICDs were
the subject of this initial inquiry, dual-chamber pacemaker
indications are also being actively scrutinized, and PCI is
likely to receive similar attention.
In the recently published study by Al-Khatib et al. (2),
using data from the National Cardiovascular Data Registry
of 111, 707 primary prevention ICD patients, 22.5% were
found to have received an ICD for non evidence-based
indications. These included 62% with newly diagnosed
heart failure, 37% who were within 40 days of an MI, 12%
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failure, and 3% within 3 months of bypass surgery (unfor-
tunately, PCI data were not included). The findings re-
ported by the researchers in combination with the DOJ
investigations has resulted in a dramatic decline in the
number of patients undergoing ICD implantation in the
United States.
As electrophysiologists who have been based at an aca-
demic teaching hospital, our practice has also directed
electrophysiology (EP) programs at neighboring nonteach-
ing facilities. The largest and busiest of our affiliates is a
tertiary-care hospital located in a suburban community.
This past year, the local hospital administration was in-
formed that an initial analysis of claims submitted to CMS
might have included patients who should have been ex-
cluded from coverage of ICD implantation. The total
number of identified patients was 229, representing 8.7% of
all de novo (nonresynchronization) ICD implants for pri-
mary prevention during the period of 2003 to 2010 reim-
bursed by Medicare. Patients were excluded largely because
of timing relative to clinical events or interventions but not
because of other exclusions, reflecting that this distribution
is a function of identification of cases based on coding
inconsistencies (Table 2).
A site visit with lawyers representing the DOJ and CMS
was scheduled. As director of the EP program, one of us
(J.S.S.) was asked to provide expert assistance to the
hospital’s administrative and legal teams. This narrative will
describe the process by which an intense internal review was
conducted and adjudicated; how a system of responses to
the audit was developed that either conceded excluded
implants or attempted to justify other implants despite
possible coding transgressions; and how a set of controls was
subsequently enacted to prevent any future departures from
standards of care and coding and claim submission regula-
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other institutions, and their physicians, administrators, and
lawyers, and, indeed, many colleagues have contacted us to
share our thoughts.
An experienced cardiology quality assurance registered
nurse performed the initial review of cases. All source
material in medical records was examined, and summaries of
each patient were entered into a spreadsheet. Particular
attention was focused on the alleged coding discrepancy, as
patients had been identified based on CPT coding entries
that were incompatible with ICD indication. This prelim-
inary review and summary were presented for EP oversight,
and it was apparent that many incompatible diagnosis and
procedure codes were prevalent. We decided that a com-
plete medical record review would be required to determine
whether clinical circumstances dictated technical violation
of CMS guidelines, whether coding entries were incorrect,
or whether there were genuine non-guideline implantations.
Each patient’s chart was retrieved, and all relevant compo-
nents extracted and bundled for detailed review by EP.
During this phase of detailed review, it became evident
that a small number of implants were not indicated (n 34,
1.3% of all implants and 15% of the targeted subgroup);
most commonly, these were implanted after bypass surgery
in the setting of nonsustained ventricular tachycardia (VT)
and/or a positive EP study. On the other end of the
spectrum were cases that were clearly secondary prevention
but the index cardiac arrest or VT event were documented
in the records of another hospital before transfer for the
ICD. The vast majority of ICD case indications was more
nuanced and highlighted the complexity of adjudicating
between clinical practice and the contemporary regulatory
environment. These cases could be categorized into 5
groups (Table 3): 1) secondary prevention indication when
the presentation was syncope in the setting of cardiomyop-
athy; 2) concurrent trivial cardiac enzyme leak or enzyme
elevation for non-MI reasons but coded as acute MI;
3) ICD implantation when the precipitating acute device
need was bradycardia and pacemaker indication; 4) incom-
plete or incidental percutaneous revascularization not antic-
ipated to have any meaningful effect on chronic LV dys-
function; and 5) ICD implantation near the end of the
90-day post-revascularization period when the patient was
admitted for heart failure. These categories represented
real-life situations encountered in our care of patients, and
we believed that ICD implantation was generally justifiable,
even at times in violation of the NCD directives.
Unexplained syncope in a patient with severe LV dys-
function is usually due to sustained hypotensive VT and is
considered a very high risk clinical event that warrants
secondary protection by an ICD even if VT is not clinically
documented (1).
The advent of high-sensitivity cardiac enzyme assays has
made management of acute coronary syndrome more in-
formed, but these enzymes are also positive in a variety of
clinical settings not indicative of acute MI, including heartfailure exacerbation, atrial fibrilla-
tion, cardioversion, and noncar-
diac events. In addition, a patient
with long-standing ischemic cardio-
myopathy with well-documented
severe LV dysfunction who pres-
ents with a small enzyme leak from
ischemia is very different from the
patient with an initial presentation
of acute ST-segment elevation MI
and positive enzymes. Indeed, the
NCD also indicates that positive
enzymes alone are not a criterion
for the diagnosis of an acute MI.
These former subsets of patients
may have been recognized as “MI”
for coding purposes but from a
clinical perspective are managed
quite differently and have a prog-
nosis including risk of sudden cardiac death governed by the
pre-existing LV dysfunction.
There is a need for pacemaker implantation in a small
proportion of acute MI patients and cardiac surgical patients
for bradycardia indications. If these patients have had severely
reduced LV function in the past, physicians are faced with a
serious quandary: implant a pacemaker and upgrade it to an
ICD when the exclusion period of 40 days or 90 days expires,
or implant an ICD upfront to serve the dual purpose of
treating bradycardia and long-term risk of serious ventricular
tachyarrhythmias. The first approach, which does not violate
the NCD exclusion criteria, exposes a large percentage of
patients to the risks of an upgrade procedure that are actually
greater than primary implant surgery. The latter approach,
which may violate the NCD exclusion criteria, will expose a
small percentage of patients to an unnecessary ICD if LV
function improves sufficiently during the waiting phase. This
decision analysis is highly representative of the possible con-
flicts that exist in day-to-day practice, given reimbursement
regulations; we have often opted to implant the ICD rather
than the pacemaker on the grounds that it is in the patient’s
best interests when the clinical context virtually guarantees that
LV function will remain depressed.
Another frequently encountered clinical scenario is the
patient with known cardiomyopathy who is admitted for heart
failure exacerbation. Many of these patients will undergo a
coronary angiogram, and if an obstructive lesion is identified,
will almost always have a PCI performed. Because these
patients have well-established ventricular dysfunction and be-
cause the coronary intervention is not in the setting of
ST-segment elevation MI, it is highly unlikely to substantially
improve LV function (3). Moreover, the necessity for heart
failure hospitalization places the patient in a very high risk
category for near-term cardiac events, including arrhythmic
death (4). We have often attempted to provide maximum
protection for these patients with an ICD. Alternative ap-
Abbreviations
and Acronyms
CMS  Centers for
Medicare and Medicaid
Services
DOJ  Department of
Justice
EP  electrophysiology
ICD  implantable
cardioverter-defibrillator
MI  myocardial infarction
NCD  National Coverage
Determination
PCI  percutaneous
coronary intervention
VT  ventricular
tachycardiaproaches such as deferred ICD for another 3 months or use of
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tion simply to satisfy administrative constraints.
Finally, the 90-day exclusion period after revasculariza-
tion cannot always be considered an inviolable barrier to
ICD implantation. It is not in the patient’s interest to defer
protection of an ICD when the expiration of the 90 days is
imminent and the patient is in a very high risk category,
such as heart failure decompensation. It is intuitive that
nothing will change in the patient’s risk profile if a few more
days elapse, and of course sudden death can strike at any
Centers for Medicare and Medicaid Services National Coverage DeTable 1 Centers for Medicare and Medicaid Services National
Covered indications:
1. Documented episode of cardiac arrest due to ventricular fibrillation (VF), not du
2. Documented sustained ventricular tachyarrhythmia (VT), either spontaneous or
infarction (MI) and not due to a transient or reversible cause (effective Ju
3. Documented familial or inherited conditions with a high risk of life-threatening
Additional indications effective for services performed on or after October 1, 2003:
4. Coronary artery disease with a documented prior MI, a measured left ventricula
(The MI must have occurred 40 days before defibrillator insertion. The
5. Documented prior MI and a measured LVEF 0.30 and a QRS duration of 12
after January 27, 2005). Patients must not have:
a. New York Heart Association (NYHA) functional class IV;
b. Cardiogenic shock or symptomatic hypotension while in a stable baseline rhy
c. Had coronary artery bypass graft surgery (CABG) or percutaneous translumin
d. Had an enzyme-positive MI within past month (effective for services on or aft
e. Clinical symptoms or findings that would make them a candidate for coronar
f. Any disease, other than cardiac disease (e.g., cancer, uremia, liver failure), as
Additional indications effective for services performed on or after January 27, 2005
6. Patients with ischemic dilated cardiomyopathy (IDCM), documented prior MI, N
7. Patients with nonischemic dilated cardiomyopathy (NIDCM) 9 months, NYHA
8. Patients who meet all current Centers for Medicare & Medicaid Services (CMS)
NYHA functional class IV heart failure.
All indications must meet the following criteria:
a. Patients must not have irreversible brain damage from pre-existing cerebral dis
b. MIs must be documented and defined according to the consensus document o
the Redefinition of Myocardial Infarction (see end);
c. Indications 3 to 8 (primary prevention of sudden cardiac death) must also mee
1) Patients must be able to give informed consent;
2) Patients must not have:
i. Cardiogenic shock or symptomatic hypotension while in a stable baseline r
ii. Had a CABG or PTCA within the past 3 months;
iii. Had an acute MI within the past 40 days;
iv. Clinical symptoms or findings that would make them a candidate for coro
v. Any disease, other than cardiac disease (e.g., cancer, uremia, liver failure),
c. Patient’s ejection fractions must be measured by angiography, radionuclide s
d. The beneficiary receiving the defibrillator implantation for primary prevention
investigational device exemption (IDE) clinical trial (42 CFR §405.201), a
§310.1), or a qualifying data collection system including approved clinic
maintained using a data submission mechanism that is already in use b
Care (IFMC) a Quality Improvement Organization (QIO) contractor for det
data elements are specified in this decision (Appendix VI) and are the m
will be completed using the ICDA (ICD Abstraction Tool) and transmitted
database. Additional stakeholder-developed data collection systems to a
specified in this decision, must meet the following basic criteria:
i. Written protocol on file;
ii. Institutional review board review and approval;
iii. Scientific review and approval by 2 or more qualified individuals who are n
iv. Certification that investigators have not been disqualified.moment. Furthermore, although we know that ICDs arenot effective within 40 days of an acute MI (1), we really do
not know the role of the ICD in the first 3 months of heart
failure diagnosis or post-revascularization because these
patients were excluded from clinical trials. Thus, there is
sometimes a lingering sense of concern that some of these
patients will die suddenly while waiting for an ICD.
We found the government legal team highly knowledge-
able and informed. The lawyers listened thoughtfully to our
presentation about the results of our review and how we
viewed the balance between complying with the letter of
nation for Implantable Automatic Defibrillatorsrage Determination for Implantable Automatic Defibrillators
transient or reversible cause (effective July 1, 1991).
d by an electrophysiology (EP) study, not associated with an acute myocardial
999).
ch as long-QT syndrome or hypertrophic cardiomyopathy (effective July 1, 1999).
tion fraction (LVEF) 0.35, and inducible, sustained VT or VF at EP study.
t must be performed 4 weeks after the qualifying MI.)
(the QRS restriction does not apply to services performed on or
nary angioplasty (PTCA) within past 3 months;
uary 27, 2005, patients must not have an acute MI in the past 40 days);
scularization; or
ed with a likelihood of survival 1 year.
ass II and III heart failure, and measured LVEF 35%;
I and III heart failure, and measured LVEF 35%;
ge requirements for a cardiac resynchronization therapy (CRT) device and have
int European Society of Cardiology/American College of Cardiology Committee for
llowing criteria:
;
vascularization;
iated with a likelihood of survival 1 year;
g, or echocardiography;
olled in either a Food and Drug Administration (FDA)-approved category B
nder the CMS Clinical Trial Policy (National Coverage Determination [NCD] Manual
s and registries. Initially, an implantable cardiac defibrillator (ICD) database will be
care participating hospitals to submit data to the Iowa Foundation for Medical
tion of reasonable and necessary and quality improvement. Initial hypothesis and
necessary to ensure that the device is reasonable and necessary. Data collection
et (Quality Network Exchange) to the IFMC, who will collect and maintain the
t or replace the initial QNet system, addressing at a minimum the hypotheses
t of the research team;
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present harm to the patients simply to satisfy the coding
guidelines and, in large part, were receptive to the “excep-
tions” that are detailed in the preceding text.
In response to the arduous review process after the DOJ
inquiry, we made several important changes. Coders have
been educated that not every patient with positive cardiac
enzymes is coded as an MI, and other clinical criteria and
ContinuedTable 1 Continued
For purposes of this coverage decision, CMS will determine whether specific registri
e. Providers must be able to justify the medical necessity of devices other than
9. Patients with NIDCM 3 months, NYHA functional class II or III heart failure, an
a. Patients must be able to give informed consent;
b. Patients must not have:
i. Cardiogenic shock or symptomatic hypotension while in a stable baseline r
ii. Had a CABG or PTCA within the past 3 months;
iii. Had an acute MI within the past 40 days;
iv. Clinical symptoms or findings that would make them a candidate for coro
v. Irreversible brain damage from preexisting cerebral disease;
vi. Any disease, other than cardiac disease (e.g., cancer, uremia, liver failure)
c. Ejection fractions must be measured by angiography, radionuclide scanning,
d. MIs must be documented and defined according to the consensus document
for the Redefinition of Myocardial Infarction (see the end of this Table);
e. The beneficiary receiving the defibrillator implantation for this indication is e
under the CMS Clinical Trial Policy (NCD Manual §310.1), or a prospectiv
i. Written protocol on file;
ii. Institutional review board review and approval;
iii. Scientific review and approval by 2 or more qualified individuals who are n
iv. Certification that investigators have not been disqualified.
For purposes of this coverage decision, CMS will determine whether specific registri
f. Providers must be able to justify the medical necessity of devices other than
Either one of the following criteria satisfies the diagnosis for an acute, evolving or re
1. Typical rise and gradual fall (troponin) or more rapid rise and fall (creatine kina
the following:
a. Ischemic symptoms;
b. Development of pathologic Q waves on the electrocardiogram (ECG);
c. ECG changes indicative of ischemia (ST-segment elevation or depression); or
d. Coronary artery intervention (e.g., coronary angioplasty).
2. Pathologic findings of an acute MI
Any 1 of the following criteria satisfies the diagnosis for established MI:
1. Development of new pathologic Q waves on serial ECGs. The patient may or m
have normalized, depending on the length of time that has passed since
2. Pathology findings of a healed or healing MI.
Primary Reasons Cases Were Identifiedas Exclud d on the Ba is of NCD Crit riaTable 2 Primary Rea ons ases Were Identifiedas Excluded on the Basis of NCD Criteria
Category Proportion
Within 90 days of revascularization 53%
Within 40 days of acute myocardial infarction 30%
Both recent myocardial infarction and revascularization 17%
Survival 1 year 0%
Cardiogenic shock 0%
Symptoms necessitating coronary revascularization 0%
Irreversible brain damage 0%
Class IV heart failure 0%
Recent diagnosis of nonischemic cardiomyopathy 0%NCD  National Coverage Determination.review mechanisms were implemented. Each ICD implant
undergoes a concurrent peer review during a morning
conference call of practicing EPs. The implanting EP must
also complete a form at the implant procedure that requires
identification of the indication for ICD and that all exclu-
sions are absent. Mitigating circumstances, as defined pre-
viously, must be included and detailed if present. Finally, a
post-hoc review is routinely undertaken by quality assurance
nursing staff, and all questionable implants are referred for
additional independent physician review.
Justification for ICD Procedurestha Potentially Violated CMS GuidelinesTable 3 Justification for ICD Proceduresthat Potentially Violated CMS Guidelines
Category Proportion
Cardiac enzyme leak 19%
Need for permanent pacemaker 19%
Incidental percutaneous coronary intervention 38%
Syncope 17%
End of 40 or 90-day exclusion period 7%
linical trials meet these criteria:
-lead devices. This justification should be available in the patient’s medical record.
sured LVEF 35%, only if the following additional criteria are also met:
;
vascularization;
iated with a likelihood of survival 1 year;
ocardiography;
Joint European Society of Cardiology/American College of Cardiology Committee
in either an FDA-approved category B IDE clinical trial (42 CFR §405.201), a trial
collection system meeting the following basic criteria:
t of the research team;
linical trials meet these criteria:
lead devices. This justification should be available in the patient’s medical record.
I:
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tainly variable, although our experience suggests a more com-
plex dynamic based on clinical context. It is also suggested that
reimbursement regulations are often in conflict with more
flexible, nimble, and updated published guidelines. The latter
are based on evolving medical evidence and created by com-
mittees of experts. It is these published and vetted pathways
that have precedence in guiding physicians regarding who
requires an ICD and when it should be implanted. The NCDs
should be updated to reflect these dynamic documents or
consider ceding authority to them.
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